Comparison of Clinico-Physiologic and CT Imaging Risk Factors for COPD Exacerbation by Yoo, Jung-Wan et al.
© 2011 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Comparison of Clinico-Physiologic and CT Imaging Risk Factors 
for COPD Exacerbation 
To date, clinico-physiologic indices have not been compared with quantitative CT 
imaging indices in determining the risk of chronic obstructive pulmonary disease 
(COPD) exacerbation. We therefore compared clinico-physiologic and CT imaging 
indices as risk factors for COPD exacerbation in patients with COPD. We 
retrospectively analyzed 260 COPD patients from pulmonary clinics at 11 hospitals in 
Korea from June 2005 to November 2009 and followed-up for at least one year. At 
the time of enrollment, none of these patients had COPD exacerbations for at least 
2 months. All underwent clinico-physiologic and radiological evaluation for risk 
factors of COPD exacerbation. After 1 yr, 106 of the 260 patients had at least one 
exacerbation of COPD. Multiple logistic regression analysis showed that old age, 
high Charlson Index, and low FEV1 were significant in a clinico-physiologic model, 
with C-statistics of 0.69, and that increased age and emphysema index were 
significant in a radiologic model, with C-statistics of 0.64. The difference between 
the two models was statistically significant (P = 0.04 by bootstrap analysis). 
Combinations of clinico-physiologic risk factors may be better than those of imaging 
risk factors in predicting COPD exacerbation.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major dis-
ease that is expected by 2020 to be the fifth most common cause 
of morbidity and the third most common cause of mortality world-
wide (1, 2). COPD patients experience exacerbation of COPD an 
average of 1.3 times per year (3). Exacerbation aggravates lung 
function decline (4) and has a negative impact on morbidity, 
mortality (5), and quality of life (6). The costs of exacerbations 
are estimated to represent 35%-60% of the total direct costs as-
sociated with COPD (7-9). Hence, the prevention of COPD ex-
acerbation is considered an important management goal. Among 
the risk factors associated with exacerbations are old age (10), low 
body mass index (11), gastroesophageal reflux disease (GERD) 
symptoms (12, 13), chronic productive cough (10, 14), severity 
of COPD and past history of exacerbations (15). Certain groups 
of patients are more susceptible to COPD exacerbations, irrespec-
tive of COPD severity (16) and a model has been developed to 
assess the risks of COPD exacerbations in patients with moder-
ate-to-very severe COPD (10). 
  Advanced CT techniques were recently shown to have a po-
tential application in assessing and monitoring COPD exacer-
bations in patients with COPD, with correlations of clinical and 
physiologic indices with CT-assessed pulmonary emphysema 
and airway dimension (17-19). Furthermore, CT-assessed em-
physema was found to correlate with mortality in patients with 
COPD (20, 21). In contrast, the presence, severity, and distribu-
tion of emphysema on CT were found to have little impact on 
clinical indices, including dyspnea score, frequency of exacer-
bation, six minute walk distance, St. George Respiratory Ques-
tionnaires score and BODE index (a composite index of body 
mass index, airflow obstruction, dyspnea, and exercise capaci-
ty). In patients with mild-to-moderate COPD, it is unclear wheth-
er CT indices, such as emphysema, airway thickening and air 
trapping, are related to the development of COPD exacerbations 
(22). There is a report including clinico-physiologic and emphy-
sema index, one of CT indices of COPD for evaluation of risk 
factors (16). However, other CT indices representing the bron-
chus and small airway as well as emphysema index have not 
been compared with clinico-physiologic indices. We have there-
fore compared clinico-physiologic and CT imaging indices as 
risk factors for COPD exacerbation in patients with COPD.
 
MATERIALS AND METHODS
Patients
This study is a part of the ongoing Korean Obstructive Lung Dis-
ease (KOLD) Cohort, in which a total of 800 patients with COPD 
or asthma will have been enrolled by 2012. For this study, we 
retrospectively analyzed 260 patients who had been recruited 
from pulmonary clinics in 11 hospitals throughout Korea from 
June 2005 to November 2009 and were followed up for at least 
one year. All 260 patients fulfilled the following three criteria: 
post-bronchodilator ratio of FEV1 to forced vital capacity (FEV1/
FVC) < 0.7 after administration of 400 µg of inhaled albuterol, 
more than 10 pack-years of smoking history, and no or minimal 
abnormality on chest radiography. Moreover, none of these pa-
tients had exacerbations of COPD for at least 2 months at the 
time of enrollment. 
Definition and confirmation of COPD exacerbation
Acute exacerbations were defined as worsening symptoms (dys-
pnea, cough, or sputum) requiring treatment with systemic ste-
roids or antibiotics, a visit to the emergency room, and/or admis-
sion to a hospital, as decided by attending physicians.
Clinico-physiologic indices for COPD 
Demographic and clinical data collected from all patients includ-
ed age, sex, smoking status, cigarette smoking amount, GERD 
treated with medications such as proton pump inhibitors, and 
hospitalization due to exacerbation of COPD within 1 yr before 
enrollment. Comorbidities were assessed using the Charlson 
index, which has been shown to be a good predictor of progno-
sis in patients with COPD (23). Body mass index was calculated 
as the weight in kilograms divided by height in meters squared 
(kg/m
2). Productive cough was defined as an affirmative answer 
to the question, “Did you cough up phlegm (in the morning or 
during the day) for at least 3 months each year during the past 
two years?” Dyspnea was assessed with the Modified Medical 
Research Council Dyspnea Scale (MMRC). The 6-min walking 
distance test was performed according to American Thoracic 
Society guidelines, except for the short distance of 20 meters. 
Health-related quality of life was assessed using the St. George 
Respiratory Questionnaire. Spirometry was performed using 
the Vmax 22 (SensorMedics, Yorba Linda, CA, USA; PFDX instru-
ment; MedGraphics, St. Paul, MN, USA) (24).
CT indices for COPD assessment 
CT indices for COPD assessment included the emphysema in-
dex, air-trapping index and airway dimensions. (17, 25-27). Pa-
tients underwent volumetric CT scans at full inspiration and ex-
piration using a 16-MDCT scanner (CT machines of three man-
ufacturers: the Somatom Sensation 16, Siemens Medical Solu-
tions, Forchheim, Germany; the GE Lightspeed Ultra, General 
Electric Healthcare, Milwaukee, WI; and the Philips Brilliance 
16, Philips Medical Systems, Best, Netherlands) (19). Scan pa-
rameters included 0.75-mm collimation, 100 effmAs, 140 kVP, 
and pitch 1.0. The scale of attenuation coefficients in this CT 
scanner ranges from -1,024 to 3,072 HU. Patients were scanned 
craniocaudally, with both scans performed in the supine posi-
tion. Images were reconstructed using a soft kernel (B30f; Sie-
mens Medical Systems) from the thoracic inlet to the lung base. Yoo J-W, et al.  •  Risk Factors for COPD Exacerbation 
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  The emphysema index was determined by automatic calcu-
lation from CT data of the volume fraction of the lungs below 
-950 Hounsfield Units at full inspiration and the mean lung den-
sity (26). The CT air-trapping index was defined as the ratio of 
mean lung density on expiration and inspiration (19). Airway 
dimensions were measured near the origin of the four segmen-
tal bronchi (RB1, LB1+2, RB10, LB10) by a consensus of two ra-
diologists using in-house software. Airway dimensions, includ-
ing the wall area (WA), lumen area (LA), and wall area percent 
(WA %), defined as WA/(WA+LA) × 100, were measured in each 
segmental bronchus. 
Statistical analysis
Continuous data and the frequencies and percentages of cate-
gorical data were expressed as mean ± standard deviation. A 
stepwise backward multiple logistic regression was used to con-
struct models predictive of COPD exacerbation. Clinico-physi-
ologic indices with a univariate P value < 0.2 were considered 
candidates in the backward stepwise multiple logistic regression. 
All three radiologic indices, irrespective of the result of univari-
ate analysis, as well as age and gender, were included in the mul-
tiple logistic regression. The predictive accuracy of the models 
was quantified by calculating the C-statistics. The two models 
were compared by bootstrap analysis using R 2.12.0 (R Devel-
opment Core Team, GNU General Public License, www.r-proj-
ect.org). In addition, we performed a multiple logistic regres-
sion analysis with all of the variables including both clinico-phys-
iologic indices and radiologic indices. All other statistical analy-
ses were performed using a statistical package (SPSS version 
12.1.1; SPSS, Chicago, IL, USA). 
Ethics statement
This study was approved by the institutional review board of 
Asan Medical Center (Approval No. 2005-0345) and of other 10 
hospitals. Written informed consent was obtained from all sub-
jected patients.
RESULTS
Patient characteristics
The clinical, physiologic, and radiologic characteristics of the 
260 patients are shown in Table 1. According to the Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 
most patients had moderate-to-severe COPD. During the previ-
ous year, 24 (9.2%) patients had been hospitalized for COPD ex-
acerbation. The mean Charlson index score in all 260 patients 
was 0.24. Fifty patients (19.2%) had at least one comorbidity, with 
diabetes mellitus being the most frequent (Table 2). 
Comparison of characteristics between exacerbators and 
non-exacerbators 
A total of 106 (40.8%) of 260 patients had experiences of acute 
exacerbation of COPD during 1 yr follow-up, who were desig-
nated as exacerbators. The characteristics of exacerbators and 
non-exacerbatiors were summarized in Table 3. Exacerbators 
were older and had more experiences of hospitalization due to 
COPD exacerbations, more dyspnea scale, worse quality of life 
and exercise capacity, lower FEV1, more emphysematous change 
and air-trapping on CT. Eighteen patients (17%) of 106 exacer-
bators were hospitalized for the treatment of COPD acute exac-
erbations during follow-up period. 
Table 1. Baseline characteristics of the subjects
Characteristics Findings
Number of subjects  260
Age (yr) 66.2 ± 7.2
Gender, number of men (%) 252 (96.9)
Amount of cigarette smoking (pack-years)   47.9 ± 26.5
Number of current smokers (%)   92 (35.4)
Number of subjects who experienced hospitalization due to 
exacerbation during past one year (%)
24 (9.2)
Charlson index score (mean)    0.2 ± 0.6
*Presence of gastroesophageal reflux disease (%)   5 (1.9)
Body mass index (kg/m
2) 23.0 ± 3.4
Number of subjects who experienced productive cough (%)   31 (11.9)
Modified MRC dyspnea scale   1.6 ± 1.1
6-minute walk distance (meters) 435.9 ± 88.0
St. George Respiratory Questionnaires score    35.0 ± 18.6
Post-bronchodilator FEV1 (% predicted)   53.1 ± 16.3
Post-bronchodilator FVC (% predicted)   81.8 ± 16.8
Indices of computed tomography
   Emphysema index (%)
   Wall area (%)
   Airtrapping index (%)
 
  24.2 ± 15.8
66.4 ± 5.0
94.7 ± 3.5
Data are presented as mean ± standard deviation. Numbers in parentheses are per-
centage of subjects. *Physician-diagnosed gastroesophageal reflux disease. Modified 
MRC, Modified Medical Research Council; FEV1, Forced expiratory volume in 1 sec-
ond; FVC, Forced vital capacity; Emphysema index, the volume fraction of the lung 
below -950 Hounsfield Units (HU) at full inspiration. Wall area, % = wall area/(wall 
area + lumen area) × 100. Airtrapping index = ratio of mean lung density on expira-
tion and inspiration × 100.
Table 2. Comorbidities of the subjects
Comorbidities
Number of patients with 
comorbidity (%)
Diabetes without complication  20 (7.7)
Peptic ulcer disease  11 (4.2)
Mild liver disease    8 (3.1)
Congestive heart failure   5 (1.9)
Cerebrovascular disease   5 (1.9)
Myocardial infarction    4 (1.5)
Peripheral vascular disease   2 (0.8)
Moderate or severe kidney disease    2 (0.8)
Solid tumor without metastasis   2 (0.8)
Others*   4 (1.5)
Any comorbidities above   50 (19.2)
*Others include dementia, connective tissue disease, diabetes with organ disease, or 
hemiplegia.Yoo J-W, et al.  •  Risk Factors for COPD Exacerbation 
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Univariate analysis of risk factors for COPD exacerbation
Table 4 shows the univariate analysis for factors predictive of 
COPD exacerbation. Among clinico-physiologic indices, we 
found that old age, current smoking, hospitalization for exacer-
bation of COPD during the previous year, Charlson index score, 
BMI, MMRC dyspnea scale, six minute walk distance, the St. 
George Respiratory Questionnaire and FEV1 were related to 
COPD exacerbation. Among the CT imaging indices, emphyse-
ma and CT air-trapping index were related to exacerbation. 
Multivariate models of risk factors for COPD exacerbation 
We utilized multiple logistic regression analysis to develop mod-
els of risk factors for COPD exacerbation (Table 5, 6). A model 
using clinico-physiologic indices showed that increased age, 
higher Charlson Index, and lower FEV1 were significantly asso-
ciated with exacerbation of COPD, with C-statistics of 0.69. A 
CT imaging model showed that increased age and emphysema 
index were associated with COPD exacerbation, with C-statistics 
of 0.64. Bootstrap analysis showed that the clinico-physiologic 
model was significantly superior to the CT imaging indices mod-
el in predicting the occurrence of exacerbations of COPD (P =  
0.04, bootstrap analysis).
  When a multiple logistic regression analysis was performed 
with all of the variables including both clinico-physiologic indi-
ces and radiologic indices, only Charlson Index was a significant 
risk factor of COPD exacerbation (Table 7). When the same anal-
ysis was done for hospitalizatioin due to COPD exacerbation as 
a dependent variable, the St. George Respiratory Questionnaires 
Table 3. Comparison of characteristics between exacerbators and no exacerbators
Variables 
Exacerbators 
(N = 106)
No Exacerbators 
(N = 154)
P value
Age (yr) 67.6 ± 7.1 65.3 ± 7.2 0.01
Gender, men, No. (%) 103 (97.2) 148 (96.7) 1.000
Amount of cigarette smoking
   (pack-years)
  46.4 ± 23.7   49.1 ± 28.2 0.590
Number of current smokers (%)   31 (29.2)   61 (39.6) 0.086
Hospitalization due to exacerbation 
   during past one year, No. (%)
  16 (15.1)   8 (5.2) 0.01
Charlson index score    0.3 ± 0.6   0.2 ± 0.6 0.198
Presence of gastroesophageal 
   reflux disease, No. (%) 
  1 (0.9)   4 (2.6) 0.65
Body mass index (kg/m
2) 22.6 ± 3.9 23.3 ± 3.0 0.08
Productive cough, No. (%)   13 (12.3)   18 (11.7) 0.89
Modified MRC dyspnea scale   1.8 ± 0.9   1.5 ± 0.0 0.013
6-minute walk distance (meters) 425.8 ± 87.3 443.1 ± 88.1 0.04
St. George Respiratory 
Questionnaires score   39.9 ± 18.6   31.6 ± 17.8 0.001
Post-bronchodilator FEV1 
   (% predicted) 
  48.6 ± 15.3   56.1 ± 16.3 0.001
CT Emphysema index (%)   27.3 ± 17.0   21.9 ± 14.4 0.02
CT Wall area (%) 66.6 ± 4.9 66.3 ± 5.1 0.65
CT Air trapping index (%) 95.1 ± 3.8 94.4 ± 3.2 0.01
Data are presented as mean ± standard deviation. Numbers in parentheses are per-
centage of subjects. FEV1 = Forced expiratory volume in 1 second; FVC, Forced vital 
capacity; Emphysema index, the volume fraction of the lung below -950 Hounsfield 
Units (HU) at full inspiration; Wall area, % = wall area/(wall area + lumen area)  × 100. 
Air trapping index, ratio of mean lung density on expiration and inspiration  × 100.
Table 4. Univariate analysis for the risk factors of COPD exacerbation
Variables  Odds ratio
95% confidence  
interval (CI)
P value
Age (yr) 1.05 1.01-1.09 0.01
Gender (men)  0.87 0.20-3.71 0.85
Amount of cigarette smoking
   (pack-years)
0.996 0.99-1.01 0.42
Current smoking 0.630 0.37-1.07 0.09
Hospitalization due to exacerbation  
   during past one year 
3.24 1.33-7.89 0.01
Charlson index score  1.50 0.81-2.80 0.199
Presence of gastroesophageal  
   reflux disease 
0.36 0.04-3.24 0.36
Body mass index 0.93 0.87-1.00 0.06
Productive cough 1.06 0.49-2.26 0.89
Modified MRC dyspnea scale 1.315 1.04-1.67 0.025
6-minute walk distance (meters) 0.99 0.99-1.00 0.13
St. George Respiratory 
Questionnaires score 1.03 1.01-1.04 0.001
Post-bronchodilator FEV1 
   (% predicted) 
0.97 0.96-0.99 0.001
CT Emphysema Index (%) 1.02 1.01-1.04 0.01
CT Wall area (%) 1.01 0.96-1.07 0.63
CT Air trapping index (%) 1.07 0.99-1.15 0.09
COPD exacerbations were defined as worsening symptoms (dyspnea , cough, or spu-
tum) requiring treatment with systemic steroids or antibiotics, a visit to the emergen-
cy room, and/or admission to a hospital which were decided by attending physicians.
Table 5. A multivariate logistic regression model for the risk factors of COPD exacer-
bation using conventional clinical and physiological information
Variables  Odds ratio 95% CI  P value
Age (yr) 1.05 1.01-1.09 0.02
Hospitalization due to exacerbation 
   during past one year 
2.34 0.87-6.30 0.09
Charlson index score  2.07 1.04-4.11 0.04
Post-bronchdilator FEV1 (% predicted) 0.97 0.96-0.99 0.002
Hosmer-Lemeshow goodness-of-fit showed chi-square = 6.52 and P = 0.59, show-
ing good fit of the models; C-statistics value was 0.694. Clinico-physiologic indices 
with a univariate P value < 0.2 were considered candidates in the backward stepwise 
multiple logistic regression. Initial variables for multiple logistic regression were age, 
current smoking, hospitalization due to exacerbation during past one year, Charlson 
index score, body mass index, modified MRC dyspnea scale, 6 minute walk distance, 
St. George Rspiratory Questionnaires score, FEV1, % predicted.
Table 6. A multivariate logistic regression model for the risk factors of COPD exacer-
bation using computed tomography (CT) indices
Variables  OR 95% CI  P value
Age (yr) 1.05 1.01-1.09 0.01
Gender 0.88 0.19-3.95 0.86
Emphysema Index  1.02 1.00-1.04 0.04
Wall area (%)  1.03 0.97-1.09 0.33
CT ATI (%) 1.02 0.94-1.11 0.60
Hosmer-Lemeshow goodness-of-fit showed chi-square = 10.41 and P = 0.24, show-
ing good fit of the models; C-statistics value was 0.643. ATI, air trapping index. All 
radiologic indices irrespective of the result of univariate analysis were included in the 
multiple logistic regression.Yoo J-W, et al.  •  Risk Factors for COPD Exacerbation 
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score and emphysema index were significant (data not shown).
DISCUSSION
Many clinical and physiological indices have been associated 
with COPD exacerbation (10-12, 16), with the phenotype of fre-
quent exacerbations recently suggested to be an important risk 
factor (16, 28). To evaluate risk factors for COPD exacerbation 
we designed two models, a clinico-physiologic model and a CT 
imaging model, both using multivariate linear regression. A com-
parison of the two models showed that the model using clinico-
physiologic indices was superior to the model using CT imag-
ing indices. The clinico-physiologic measurements indepen-
dently associated with COPD exacerbation over 1-yr follow-up 
were increased age, high Charlson index and low FEV1. 
  Several reports showed a relationship between quantitative 
assessment of COPD by CT and clinico-physiologic indices (17, 
19), suggesting that emphysematous changes measured by CT 
may be predictive of mortality in COPD patients. Moreover, CT- 
measured emphysematous changes have been found to predict 
respiratory mortality (21). However, little is known about the 
relationship between CT imaging indices and COPD exacerba-
tions. Although studies have included CT-determined emphy-
sematous changes as an index for prediction of COPD exacer-
bation, these associations were not clinically significant (16, 22). 
A recent study demonstrated that % wall area measuring airway 
thickness correlates with symptoms of chronic bronchitis and 
frequent exacerbation (29).
  Although our study showed that emphysema index and CT 
air-trapping index were associated with exacerbations of COPD 
in univariate analysis, only emphysema index remained signifi-
cant on multivariate analysis. However, when all of the clinical, 
physiologic and CT imaging indices were included in a multi-
variate logistic model, only the clinico-physiologic indices were 
statistically significant. Only hospitalization due to COPD exac-
erbation is limited to emphysema index, one of CT indices in 
our study, which is statistically significant by multivariate anal-
ysis. This result suggests that emphysema index may be useful 
for evaluation of the risk hospitalization due to COPD exacer-
bation. We did not find any relationship between air wall char-
acteristics on CT and frequency of exacerbations, but this may 
be a consequence of the population studied, with only 11% of 
chronic bronchitis. 
  We found that increased age and higher Charlson index score 
were risk factors for COPD exacerbation. Charlson index score, 
which is used to assess comorbidities, has been shown to be a 
good predictor of prognosis in COPD patients (23) and has been 
associated with the number of hospitalizations of COPD patients 
for any cause during the previous year (30). 
Studies of patients with COPD have shown a phenotype for fre-
quent COPD exacerbation, with prior exacerbations of COPD 
being the strongest risk factor for subsequent COPD exacerba-
tions (16). Of our 260 patients, 24 (9.2%) had been hospitalized 
at least once for COPD exacerbation during the previous year; 
however, they showed a marginally increased risk for COPD ex-
acerbation during follow-up than patients not hospitalized for 
COPD exacerbation in clinico-physiologic multivariate analysis.
  We found that other possible risk factors, such as productive 
cough and GERD, were not significant for exacerbation of COPD. 
However, few of our patients had productive cough (11.9%) or 
GERD (1.9%), which may have affected their statistical contri-
bution.
  This study had several limitations. First, considering a very 
low prevalence of comorbidities, our relatively small-sized pop-
ulation was very selective. So it is difficult to generalize our re-
sults to all patients with COPD. Second, we did not evaluate the 
number of previous exacerbations, one of the more relevant fac-
tors associated with current exacerbations, before enrollment. 
Third, we did not consider the impact of COPD medications on 
exacerbation, due to the heterogeneous use of medication dur-
ing follow-up among our patients. 
  In conclusion, a combination of clinico-physiologic risk fac-
tors may be superior to a combination of CT imaging risk fac-
tors in predicting COPD exacerbation. 
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We compared clinico-physiologic and CT imaging indices as risk factors for COPD exacerbation in 260 patients with chronic 
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